Generic pharmaceutical company Lannett Company Inc (NYSE:LCI) stated on Monday that it recorded a net loss of USD7.6m (USD0.20 per share) for its fiscal fourth quarter ended 30 June 2019.
This is an improvement in earnings when compared with a higher net loss of USD11.4m (USD0.30 per share) for the fiscal 2018 fourth quarter.
GAAP net sales of USD133.8m were recorded for its fiscal fourth quarter ended 30 June 2019, down over USD170.9m for the fourth quarter of fiscal 2018.
Research and development (R&D) expenses of USD9.4m were reported for its fiscal fourth quarter ended 30 June 2019, a rise versus R&D of USD8.3m for the fiscal 2018 fourth quarter.
Dr. Reddy's Laboratories to Acquire Select Business Divisions of Wockhardt in India
Dr. Reddy's Laboratories to purchase select business divisions of Wockhardt in India for INR18.5bn
Sun Pharma Introduces Absorica LD Capsules in USA for Management of Severe Recalcitrant Nodular Acne
Dr. Reddy's Laboratories releases Trientine Hydrochloride Capsules USP in 250 mg for US market
Towa Pharmaceutical completes acquisition of Esteve's generics division
Geneyork and Lannett Company start commercial shipment of Deltasone tablets
FDA Approves Ajovy Injection Autoinjector
Par Pharmaceutical commences shipping authorised generic version of Allergan's Carafate